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Abstract The gene encoding hepatocyte nuclear factor 4K
(HNF4K) possesses two alternative promoters responsible for
developmental and tissue-speci¢c expression of HNF4K1 and
HNF4K7. The two isoforms possess di¡erent N-termini and
exhibit distinct transactivation properties. We show here for
the ¢rst time that the e¡ects mediated by HNF4K isoforms in
concert with three di¡erent coregulators result in promoter-spe-
ci¢c responses. Transcript levels of silencing mediator for reti-
noid and thyroid receptors and glucocorticoid receptor interact-
ing protein-1 in the liver are reduced at birth, a time point when
many genes are strongly activated, suggesting that the e¡ects of
coregulators on HNF4K activity in vivo could be determined by
the levels of their expression as well as by the target promoter.
' 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The gene encoding the nuclear receptor hepatocyte nuclear
factor 4K (HNF4K) [1] possesses two alternative promoters
[2], the use of which is responsible for developmental and
tissue-speci¢c expression of the HNF4K1 and HNF4K7 iso-
forms [3,4]. The latter isoform is expressed predominantly in
the embryonic/fetal liver while only HNF4K1 is found in the
adult organ. The two isoforms possess intrinsic di¡erences in
their transactivation properties [4]. Indeed, the hepatic func-
tions expressed in the embryonic liver are mostly in common
with those of the adult, but at birth, a whole new set of func-
tions, implicated in adult hepatic metabolism, is activated.
The fetal isoform transactivates preferentially promoters of
fetal functions while the adult isoform is more active on pro-
moters of genes expressed more avidly in the adult [4].
It is known that HNF4K, like other nuclear receptors, pro-
vokes gene activation in concert with interactions with coac-
tivators and corepressors through its activation function (AF)
domains. The ability of HNF4K1 and HNF4K7 to interact
with the CREB binding protein (CBP)/p300 and p160 coac-
tivators and with silencing mediator for retinoid and thyroid
receptors (SMRT) corepressor has been explored using mainly
transactivation assays based on the Gal4 one-hybrid system
[5^8]. HNF4K1, via both the AF1 and AF2, shows enhanced
transactivation of reporter constructs in the presence of CBP
or glucocorticoid receptor interacting protein-1 (GRIP-1), and
exhibits, via the AF2, SMRT-mediated transrepression.
HNF4K7 shows similar properties, but only via the AF2,
the AF1 being absent from this isoform [7].
In this work, we explored the possible role that interactions
with these coregulators play in determining ¢ne tuning of
HNF4K activity on di¡erent target promoters by cotransfec-
tion experiments using di¡erent reporters for HNF4K. We
report that the activities elicited by these coregulators on
HNF4K-dependent transcription are dependent on the target
promoter. Interestingly, it was observed that patterns of trans-
activation/transrepression were dictated by the target pro-
moter and in almost all cases the e¡ects mediated by coregu-
lators in concert with HNF4K1 were more robust than those
observed with the same coregulators and HNF4K7.
2. Materials and methods
2.1. Plasmids
The empty pCB6 vector [9] and the CMV.HNF4K1.VSV [10] and
CMV.HNF4K7.VSV vectors [4] containing the full-length rat cDNAs
for the corresponding isoforms as well as the apolipoprotein (Apo) AI
reporter pZL.HIV.LTR.AI-4 [11], the ApoCIII.Luc reporter [12] and
the ApoB reporter [13] have all been described. Detailed description
of these reporters is provided in the legend to Fig. 1. The
pSG5.SMRT [14], pSG5.GRIP-1 [15] and pCMV.HA.p300 [16] ex-
pression vectors have been described elsewhere. The CMV.LGal plas-
mid (California Biotechnology) contains the lacZ gene under control
of the cytomegalovirus (CMV) promoter.
2.2. Transient transfections
HNF4K-de¢cient 293T [17] cells were grown in Dulbecco’s modi¢ed
Eagle’s medium supplemented with 5% fetal calf serum at 37‡C under
a 5% CO2 atmosphere. For transient transfection assays, 2U105 cells
were seeded in six-well plates and were transfected by the calcium
phosphate coprecipitation procedure 1 day later using 1 Wg of report-
er, 100 ng of CMV.LGal and various amounts of expression vectors as
indicated in the ¢gure legend. Equivalent molar amounts of empty
vector were added to equalize DNA amounts. Glycerol shock was
carried out 5 h later and cells were harvested 24 h after the shock.
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L-Galactosidase activity was measured by the standard colorimetric
method and luciferase activity was determined with a Berthold 9501
luminometer as described [18].
2.3. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA extraction from mouse liver and RT-PCR were carried
out as previously described in the presence of 1 WCi [K-32P]dCTP [4].
Primers used for SMRT cDNA ampli¢cation were 5PCACCCCA-
Fig. 1. A: E¡ects of p160 and p300 coactivators and SMRT corepressor are isoform- and promoter-speci¢c. 293T cells were cotransfected with
20 ng of empty (pCB6), HNF4K1 or HNF4K7 expression vectors and the ApoB, the ApoCIII or the ApoAI reporter together with 100 ng of
the CMV.p300.HA and/or the pSG5.GRIP-1 plasmid. For the transfections with SMRT, 50 ng of the HNF4K expression vectors together with
250 ng of pSG5.SMRT were used. Schematic representation of each of the reporters used is shown. The ApoB reporter contains the region
3262 to +122 from the human ApoB promoter linked to the ¢re£y luciferase gene. The ApoCIII reporter contains the region 3821 to +24
from the human ApoCIII gene driving the expression of the luciferase gene. The ApoAI reporter consists of four site A elements responsive to
HNF4K from the human ApoAI promoter in front of the human immunode¢ciency virus long terminal repeat driving expression of the lucifer-
ase gene. Binding sites for other transcription factors are represented as follows: GR glucocorticoid receptor, R AP2, F ARP1, b Sp1, O NF-
UB, P C/EBP, E HNF4. Luciferase activity was normalized to L-galactosidase activity. Numbers give the fold induction by HNF4K1 or
HNF4K7 on reporter gene activity relative to that with the empty vector and the fold activation elicited by the combination of p300 and/or
GRIP-1 with HNF4K1 or HNF4K7. Numbers in parentheses show the fold factor induction upon addition of p300 and/or GRIP-1 over that
of HNF4K1 or HNF4K7 alone. Repression induced by SMRT addition (see below) is expressed in percentage relative to HNF4K alone. B:
GRIP-1 can compete with SMRT in a promoter-speci¢c fashion. 293T cells were transfected with the ApoB, the ApoCIII or the ApoAI report-
er, 50 ng of the empty (pCB6), HNF4K1 or HNF4K7 expression vectors, 250 ng of pSG5.SMRT and/or 0, 50, 100, 200 or 300 ng of
pSG5.GRIP-1 as indicated. Luciferase activity was normalized to L-galactosidase activity. All the experiments are shown as the meanQS.E.M.
of a representative experiment performed in triplicate (some of the error bars are too small to be visible in the ¢gure).
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CAGCAAAGTTCAG and 5PGCTGAGGACGAAGAGATGGA,
and for GRIP-1 5PACACTAGCACCATGAGAGCC and 5PTCGC-
TTGTCCAGTCAGATCC. Ampli¢cation was carried out for 25 and
18 cycles for SMRT/GRIP-1 and ribosomal RNA, respectively. 28S
ampli¢cation was visualized with ethidium bromide. It was veri¢ed
that the number of cycles chosen for PCR ensured analysis within the
exponential phase of ampli¢cation for all of the primers used.
3. Results and discussion
Here, we have examined the e¡ects elicited by coregulators
upon transactivation by the HNF4K isoforms expressed
mainly in fetal (HNF4K7) and adult (HNF4K1) liver. Trans-
fection experiments using reporters for HNF4 and expression
vectors for the two isoforms coupled with GRIP-1, p300 and
SMRT were performed. Since HNF4K plays a major role in
the regulation of Apo gene expression [19^21], three di¡erent
constructs derived from the regulatory sequences of the ApoB,
the ApoCIII and the ApoAI genes were used.
3.1. Robust ApoB transactivation by HNF4K isoforms was
largely independent of interacting partners
Fig. 1 presents the patterns of response of each reporter in
cotransfection assays in concert with coactivators of the p300
and the p160 (GRIP-1) family of coactivators as well as with
the SMRT corepressor. ApoB was very strongly activated by
HNF4K1, and less strongly by HNF4K7. In the presence of
either HNF4K isoform, there was a weak but signi¢cant en-
hancement by p300 (two- to three-fold) and no e¡ect of
GRIP-1. In the case of SMRT, only HNF4K1 was subject
to repression and the e¡ect was of 25%. Neither of the assays
we devised to test for coactivation by GRIP-1 was positive
with the ApoB reporter: only additive e¡ects were observed
when p300 and GRIP-1 were tested together, and GRIP-1 was
unable to titrate SMRT-mediated repression (Fig. 1). These
results are in line with the observation that GRIP-1 competes
with SMRT through binding only of HNF4K [5] and not
SMRT itself. In addition, they provide a con¢rmation that
GRIP-1 and, in the case of HNF4K7, SMRT as well are in-
active in HNF4K-mediated transactivation/transrepression of
the ApoB promoter.
3.2. The ApoCIII reporter was moderately transactivated by
both HNF4K isoforms and by p300 while GRIP-1 and
SMRT e¡ects were weak but signi¢cant
In contrast to ApoB, transactivation of ApoCIII by
HNF4K1 and HNF4K7 was only moderate (Fig. 1A). In ad-
dition, p300 provoked a large increase over the activity ob-
tained with HNF4K alone. However, the GRIP-1 e¡ect was
very small, and the two factors together resulted in purely
additive e¡ects (Fig. 1A). Concerning SMRT, the e¡ects ob-
tained were di¡erent with HNF4K1 and HNF4K7. In the
presence of the HNF4K1 isoform, SMRT caused a signi¢cant
inhibition that was e¡ectively titrated by the addition of in-
creasing amounts of GRIP-1, even though GRIP-1 itself had
only weak transactivation capacity (Fig. 1B). In the presence
of the fetal HNF4K7 isoform, SMRT had less of an e¡ect and
the addition of increasing amounts of GRIP-1 was unable to
compete the SMRT repression, even though a positive e¡ect
of GRIP-1 alone was manifest (Fig. 1B).
3.3. The ApoAI reporter was strongly transactivated by
HNF4K isoforms and by p300 and GRIP-1, while the
signi¢cant repression by SMRT was totally competed by
GRIP-1
The ApoAI reporter was the most responsive to both
HNF4K isoforms and the coregulators tested (Fig. 1). Both
isoforms strongly activated this reporter, although as ob-
served for each of the promoters used here, HNF4K1 was
more e¡ective than HNF4K7. Signi¢cant activation was medi-
ated by p300 and GRIP-1, and the combination of the two
factors induced a synergistic response, but only in combina-
tion with HNF4K1. Indeed, only HNF4K1 contains two func-
tional activation domains, AF1 and AF2, which could be a
prerequisite for such synergy [7,22]. SMRT repression was
signi¢cant with both isoforms, and in both cases a dose-de-
pendent competition of repression was obtained with GRIP-1.
3.4. Transcript levels of the SMRT and GRIP-1 coregulators
varied during liver development
The activity of transcription factors may be controlled in
part by the physiological levels of expression of coregulators.
Transcript levels of SMRT, nuclear receptor corepressor
(NCoR) and other coactivators can vary from one cell type
to another and during di¡erentiation [23,24]. Therefore, we
analyzed the levels of transcripts encoding SMRT and
GRIP-1 in the liver.
Fig. 2 shows the timing of expression of HNF4K isoforms
(see [4]) and the results of semi-quantitative RT-PCR for
SMRT and GRIP-1 transcripts carried out on total RNA
from mouse liver of 14.5 days post-coitum (d.p.c.), newborn,
2 weeks old and adult. It was surprising to observe that
SMRT and GRIP-1 transcripts were respectively undetectable
Fig. 2. SMRT transcripts are down-regulated in the liver at birth.
RT-PCR analysis of total mouse liver RNA from 14.5 d.p.c., 2
days and 2 weeks after birth, and adult. The same cDNA samples
were used to amplify SMRT, GRIP-1 and ribosomal 28S RNA as
internal control. RT-PCR was performed with two independent liver
RNAs and the results obtained were the same. SMRT transcripts at
day 2 remained undetectable even after overexposure of the autora-
diogram (data not shown). Below are shown the relative accumula-
tions of transcripts of the two isoforms of HNF4K determined using
the same RNA samples (experiment originally published as ¢gure 5
in [4] and summarized here).
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or down-regulated just after birth. It should be pointed out
that at 14.5 d.p.c., when SMRT and GRIP-1 transcripts were
maximal, the liver is heavily populated by hematopoietic cells,
which could be expressing these transcripts. This raises the
possibility that expression of the coactivators in hepatocytes
occurs only after birth, when the liver is no longer a hema-
topoietic organ. Even after overexposure of the autoradio-
gram, SMRT transcripts were undetectable just after birth,
a time when the liver is undergoing profound changes in
gene expression pattern, and when the activation of adult liver
functions has just taken place. Indeed, for many of these
functions HNF4K is known to play a decisive role [25] in
maintenance of expression. In the absence of the SMRT co-
repressor HNF4K would be expected to have a more robust
activating in£uence. GRIP-1 transcripts were down-regulated
at birth as well ; nevertheless, they were still present and, since
p300 is more active than GRIP-1 in the context of coactiva-
tion potential in concert with HNF4K (Fig. 1), a reduction in
GRIP-1 concentration would not be expected to compromise
HNF4K-mediated activation of gene expression at birth.
3.5. Conclusions
The observations presented here reveal novel levels of con-
trol of gene expression in the liver mediated by HNF4K, a
gene product that has been demonstrated to be essential for
expression of the di¡erentiation program of the liver in the
embryo and in the adult [20,26].
In order to understand the mechanism for the di¡erences
observed in the transactivation properties of the HNF4K1 and
HNF4K7 isoforms, we have completed our earlier studies of in
vitro interactions of HNF4K proteins with coregulators [7] by
cotransfection studies using the same interaction partners. In
addition, by examining several di¡erent promoter constructs
in parallel, with the initial aim of extending our previous ob-
servations, we observed promoter-speci¢c di¡erences in coac-
tivation and corepression of target promoters that are as great
as the di¡erences exhibited by the two isoforms. While results
from experiments that rely upon overexpression of transcrip-
tion factors and their partners must be interpreted with cau-
tion, at present the in vitro and ex vivo approaches remain the
only option when interactions among three molecules are
being studied.
For this work we have relied upon three reporter con-
structs: two of them contain real promoter fragments of 400
(ApoB) and 850 (ApoCIII) bp, and one a multimerized HNF4
binding site from the ApoAI promoter. All of these regulatory
sequences derive from genes that have been validated in vivo
as genuine HNF4K targets. Liver-speci¢c deletion of all iso-
forms of HNF4K in the mouse revealed that in 8.5 or 12.5
d.p.c. liver all three of the apolipoproteins are dramatically
down-regulated upon ablation of the HNF4K gene [19,26].
Speci¢c deletion of HNF4K in adult liver results in complete
loss of ApoCIII expression [20]. Furthermore, the levels of
ApoB and ApoCIII transcripts increase during development
to reach the levels characteristic of adult liver [27]. Thus, the
transcriptional responses that we have obtained using pro-
moter studies recapitulate those observed during develop-
ment: expression is lower during embryonic/fetal life when
the less responsive HNF4K7 isoform is expressed.
Our results show that GRIP-1 activity on HNF4K is pro-
moter-speci¢c: no activity with ApoB, only slight activity for
ApoCIII and a stronger e¡ect on ApoAI was observed. More-
over, one case of synergy through the action of the p160 and
p300 family of coactivators was observed but appeared to
exhibit the following requirements: (a) the activity of p300,
(b) substantial activity of GRIP-1 and (c) both AF modules.
These observations suggest that p300 acts as a more general
coregulator of transcription, while p160 coactivators may be
important as promoter-speci¢c determinants of nuclear recep-
tor activity. These results are in line with what has been pre-
viously suggested for the p160 coactivators [28].
Relevant transcriptional di¡erences between HNF4K1 and
HNF4K7 have been documented [7] and could account for
the promoter-speci¢c e¡ects that we now report. Namely,
HNF4K1 exhibits enhanced protease resistance compared to
HNF4K7, but only upon speci¢c DNA binding, suggesting
that HNF4K1 folds di¡erently when it binds to DNA. Indeed,
such a change could confer a di¡erent a⁄nity for corepressors
and/or coactivators in the context of particular target pro-
moters. Moreover, HNF4K7 possesses only one activation
function, AF2, that can interact with both coactivators and
corepressors. In contrast, HNF4K1 possesses two activation
functions, AF1 being able to interact only with coactivators
and AF2 with both classes of coregulators (see table 1 in [7]).
The HNF4K1 isoform is more strongly a¡ected in its trans-
activation properties by coregulators than the embryonic
HNF4K7 isoform, in accord with the fact that the promoters
of genes encoding metabolic functions of the adult liver are
often inducible. Moreover, only HNF4K1 possesses a func-
tional AF1 that could act to antagonize SMRT repression
[7]. Transcript levels of coregulators such as SMRT and
GRIP-1 that act negatively or weakly on the promoters exam-
ined are reduced at birth (Fig. 2), the time when ApoCIII and
many other genes in the liver are strongly activated. Thus, the
e¡ects of coregulators on HNF4K activity in vivo could be
determined by their levels of expression. Alternatively, dis-
crimination between activators or repressors within a single
cell could be modulated by the context of the target promoter
and/or by di¡erences in the a⁄nity displayed by isoforms of
the same nuclear receptor versus these coregulators.
In summary, we show here for the ¢rst time in a compar-
ative study that the e¡ects mediated by HNF4K isoforms in
concert with three di¡erent coregulators result in promoter-
speci¢c responses, adding a novel level of sophistication to the
regulation of liver-speci¢c gene expression. Indeed, the poten-
tial physiological relevance of the interaction of HNF4K with
these coregulators is highlighted by the fact that target genes
of the same transcription factor are activated/repressed in a
di¡erent fashion according to the combination of coregulators
recruited to target promoters.
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